Literature DB >> 21678971

Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3).

Huameng Li1, Aiguo Liu, Zhenjiang Zhao, Yufang Xu, Jiayuh Lin, David Jou, Chenglong Li.   

Abstract

We describe a novel method of drug discovery using MLSD and drug repositioning, with cancer target STAT3 being used as a test case. Multiple drug scaffolds were simultaneously docked into hot spots of STAT3 by MLSD, followed by tethering to generate virtual template compounds. Similarity search of virtual hits on drug database identified celecoxib as a novel inhibitor of STAT3. Furthermore, we designed two novel lead inhibitors based on one of the lead templates and celecoxib.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21678971      PMCID: PMC4295767          DOI: 10.1021/jm101330h

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  20 in total

1.  Stattic: a small-molecule inhibitor of STAT3 activation and dimerization.

Authors:  Jochen Schust; Bianca Sperl; Angela Hollis; Thomas U Mayer; Thorsten Berg
Journal:  Chem Biol       Date:  2006-11

2.  New uses for old drugs.

Authors:  Curtis R Chong; David J Sullivan
Journal:  Nature       Date:  2007-08-09       Impact factor: 49.962

3.  Design, synthesis, and studies of small molecule STAT3 inhibitors.

Authors:  Deepak Bhasin; Katryna Cisek; Trupti Pandharkar; Nicholas Regan; Chenglong Li; Bulbul Pandit; Jiayuh Lin; Pui-Kai Li
Journal:  Bioorg Med Chem Lett       Date:  2007-10-17       Impact factor: 2.823

4.  Stat3 as an oncogene.

Authors:  J F Bromberg; M H Wrzeszczynska; G Devgan; Y Zhao; R G Pestell; C Albanese; J E Darnell
Journal:  Cell       Date:  1999-08-06       Impact factor: 41.582

5.  Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity.

Authors:  Marcin Kortylewski; Maciej Kujawski; Tianhong Wang; Sheng Wei; Shumin Zhang; Shari Pilon-Thomas; Guilian Niu; Heidi Kay; James Mulé; William G Kerr; Richard Jove; Drew Pardoll; Hua Yu
Journal:  Nat Med       Date:  2005-11-20       Impact factor: 53.440

6.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours.

Authors:  Tilman Oltersdorf; Steven W Elmore; Alexander R Shoemaker; Robert C Armstrong; David J Augeri; Barbara A Belli; Milan Bruncko; Thomas L Deckwerth; Jurgen Dinges; Philip J Hajduk; Mary K Joseph; Shinichi Kitada; Stanley J Korsmeyer; Aaron R Kunzer; Anthony Letai; Chi Li; Michael J Mitten; David G Nettesheim; ShiChung Ng; Paul M Nimmer; Jacqueline M O'Connor; Anatol Oleksijew; Andrew M Petros; John C Reed; Wang Shen; Stephen K Tahir; Craig B Thompson; Kevin J Tomaselli; Baole Wang; Michael D Wendt; Haichao Zhang; Stephen W Fesik; Saul H Rosenberg
Journal:  Nature       Date:  2005-05-15       Impact factor: 49.962

7.  A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells.

Authors:  Hui Song; Renxiao Wang; Shaomeng Wang; Jiayuh Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-21       Impact factor: 11.205

8.  An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects.

Authors:  Khandaker A Z Siddiquee; Patrick T Gunning; Matthew Glenn; William P Katt; Shumin Zhang; Christopher Schrock; Christopher Schroeck; Said M Sebti; Richard Jove; Andrew D Hamilton; James Turkson
Journal:  ACS Chem Biol       Date:  2007-12-21       Impact factor: 5.100

9.  Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis.

Authors:  Daoyan Wei; Xiangdong Le; Leizhen Zheng; Liwei Wang; Jennifer A Frey; Allen C Gao; Zhihai Peng; Suyun Huang; Henry Q Xiong; James L Abbruzzese; Keping Xie
Journal:  Oncogene       Date:  2003-01-23       Impact factor: 9.867

10.  Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity.

Authors:  Khandaker Siddiquee; Shumin Zhang; Wayne C Guida; Michelle A Blaskovich; Benjamin Greedy; Harshani R Lawrence; M L Richard Yip; Richard Jove; Mark M McLaughlin; Nicholas J Lawrence; Said M Sebti; James Turkson
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-26       Impact factor: 11.205

View more
  23 in total

1.  Multiple ligand docking by Glide: implications for virtual second-site screening.

Authors:  Márton Vass; Ákos Tarcsay; György M Keserű
Journal:  J Comput Aided Mol Des       Date:  2012-05-26       Impact factor: 3.686

2.  Novel 2-Carbonylbenzo[b]thiophene 1,1-Dioxide Derivatives as Potent Inhibitors of STAT3 Signaling Pathway.

Authors:  Peng Ji; Xin Xu; Shuhua Ma; Junchao Fan; Qiang Zhou; Xinliang Mao; Chunhua Qiao
Journal:  ACS Med Chem Lett       Date:  2015-07-27       Impact factor: 4.345

3.  Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy.

Authors:  Haijun Chen; Zhengduo Yang; Chunyong Ding; Lili Chu; Yusong Zhang; Kristin Terry; Huiling Liu; Qiang Shen; Jia Zhou
Journal:  Eur J Med Chem       Date:  2013-01-26       Impact factor: 6.514

4.  Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation.

Authors:  Dong-bo Liu; Guang-yuan Hu; Guo-xian Long; Hong Qiu; Qi Mei; Guo-qing Hu
Journal:  Acta Pharmacol Sin       Date:  2012-04-16       Impact factor: 6.150

5.  Development of new N-Arylbenzamides as STAT3 Dimerization Inhibitors.

Authors:  Murali K Urlam; Roberta Pireddu; Yiyu Ge; Xiaolei Zhang; Ying Sun; Harshani R Lawrence; Wayne C Guida; Saïd M Sebti; Nicholas J Lawrence
Journal:  Medchemcomm       Date:  2013-06       Impact factor: 3.597

6.  Novel small molecule IL-6 inhibitor suppresses autoreactive Th17 development and promotes Treg development.

Authors:  S I Aqel; E E Kraus; N Jena; V Kumari; M C Granitto; L Mao; M F Farinas; E Y Zhao; G Perottino; W Pei; A E Lovett-Racke; M K Racke; J R Fuchs; C Li; Y Yang
Journal:  Clin Exp Immunol       Date:  2019-01-24       Impact factor: 4.330

7.  Predicting new indications for approved drugs using a proteochemometric method.

Authors:  Sivanesan Dakshanamurthy; Naiem T Issa; Shahin Assefnia; Ashwini Seshasayee; Oakland J Peters; Subha Madhavan; Aykut Uren; Milton L Brown; Stephen W Byers
Journal:  J Med Chem       Date:  2012-07-25       Impact factor: 7.446

8.  Functional characterization of TRPM7 in nasopharyngeal carcinoma and its knockdown effects on tumorigenesis.

Authors:  Yi Qin; Zhi-Wei Liao; Jing-Yan Luo; Wen-Zhe Wu; An-Shang Lu; Pu-Xia Su; Bing-Quan Lai; Xiao-Xiao Wang
Journal:  Tumour Biol       Date:  2016-01-15

9.  Considerations of Protein Subpockets in Fragment-Based Drug Design.

Authors:  Matthew Bartolowits; V Jo Davisson
Journal:  Chem Biol Drug Des       Date:  2015-08-31       Impact factor: 2.817

10.  The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation.

Authors:  S S Tarighat; R Santhanam; D Frankhouser; H S Radomska; H Lai; M Anghelina; H Wang; X Huang; L Alinari; A Walker; M A Caligiuri; C M Croce; L Li; R Garzon; C Li; R A Baiocchi; G Marcucci
Journal:  Leukemia       Date:  2015-11-05       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.